moxonidine has been researched along with Left Ventricular Hypertrophy in 10 studies
moxonidine: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Moxonidine-induced central sympathoinhibition attenuated brain oxidative stress, prevented cardiac dysfunction and remodelling, and improved the prognosis in rats with hypertensive heart failure." | 7.79 | Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure. ( Hirooka, Y; Honda, N; Ito, K; Kishi, T; Matsukawa, R; Shinohara, K; Sunagawa, K; Utsumi, H; Yasukawa, K, 2013) |
| "Moxonidine is a new centrally active imidazoline-receptor agonist being effectively applied in the treatment of arterial hypertension due to its sympathicolytic potency." | 7.71 | [Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. Effects of moxonidine on coronary circulation]. ( Hamel, M; Hamm, C; Miric, M; Mitrovic, V; Thormann, J, 2001) |
| "Moxonidine-induced central sympathoinhibition attenuated brain oxidative stress, prevented cardiac dysfunction and remodelling, and improved the prognosis in rats with hypertensive heart failure." | 3.79 | Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure. ( Hirooka, Y; Honda, N; Ito, K; Kishi, T; Matsukawa, R; Shinohara, K; Sunagawa, K; Utsumi, H; Yasukawa, K, 2013) |
| "Regression of left ventricular hypertrophy by moxonidine, a centrally acting sympatholytic imidazoline compound, results from a sustained reduction of DNA synthesis and transient stimulation of DNA fragmentation." | 3.77 | Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt. ( Aceros, H; Cobos-Puc, L; Farah, G; Mukaddam-Daher, S; Noiseux, N; Stabile, AM, 2011) |
| "Moxonidine is a new centrally active imidazoline-receptor agonist being effectively applied in the treatment of arterial hypertension due to its sympathicolytic potency." | 3.71 | [Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. Effects of moxonidine on coronary circulation]. ( Hamel, M; Hamm, C; Miric, M; Mitrovic, V; Thormann, J, 2001) |
| "Although essential hypertension is usually defined as a hemodynamic disorder, it is expressed differently among individuals and varies during progression of the disease state." | 2.67 | I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience. ( Christen, MO; Ollivier, JP, 1994) |
| "Moxonidine is an antihypertensive imidazoline compound that reduces blood pressure primarily by central inhibition of sympathetic outflow and by direct actions on the heart to release atrial natriuretic peptide, a vasodilator and an antihypertrophic cardiac hormone." | 1.35 | Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation. ( Danalache, B; DeBlois, D; Duguay, D; El-Ayoubi, R; Gutkowska, J; Menaouar, A; Mukaddam-Daher, S; Paquette, PA, 2008) |
| "Concentric left ventricular hypertrophy after MI, defined as increased cross-sectional area of transversally cut Gomori stained myocytes, was indicated by almost double myocyte size (P<0." | 1.32 | Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts. ( Saxena, PR; Schoemaker, RG; Van Kerckhoven, R; van Veghel, R, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honda, N | 1 |
| Hirooka, Y | 1 |
| Ito, K | 1 |
| Matsukawa, R | 1 |
| Shinohara, K | 1 |
| Kishi, T | 1 |
| Yasukawa, K | 1 |
| Utsumi, H | 1 |
| Sunagawa, K | 1 |
| Ripley, DP | 1 |
| Negrou, K | 1 |
| Oliver, JJ | 1 |
| Worthy, G | 1 |
| Struthers, AD | 1 |
| Plein, S | 1 |
| Greenwood, JP | 1 |
| Aceros, H | 1 |
| Farah, G | 1 |
| Cobos-Puc, L | 1 |
| Stabile, AM | 1 |
| Noiseux, N | 1 |
| Mukaddam-Daher, S | 2 |
| Van Kerckhoven, R | 1 |
| van Veghel, R | 1 |
| Saxena, PR | 1 |
| Schoemaker, RG | 1 |
| Paquette, PA | 1 |
| Duguay, D | 1 |
| El-Ayoubi, R | 1 |
| Menaouar, A | 1 |
| Danalache, B | 1 |
| Gutkowska, J | 1 |
| DeBlois, D | 1 |
| Ollivier, JP | 1 |
| Christen, MO | 1 |
| Steckelings, UM | 1 |
| Unger, T | 1 |
| Mervaala, EM | 1 |
| Malmberg, L | 1 |
| Teräväinen, TL | 1 |
| Lähteenmäki, T | 1 |
| Karjala, K | 1 |
| Paakkari, I | 1 |
| Pörsti, I | 1 |
| Mest, HJ | 1 |
| Vapaatalo, H | 1 |
| Karppanen, H | 1 |
| Baliakina, EV | 1 |
| Patrusheva, IF | 1 |
| Rynskova, EE | 1 |
| Iurenev, AP | 1 |
| Mitrovic, V | 1 |
| Hamel, M | 1 |
| Miric, M | 1 |
| Thormann, J | 1 |
| Hamm, C | 1 |
2 trials available for moxonidine and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: a cardiovascular magnetic resonance study.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aorta, Th | 2015 |
I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarke | 1994 |
8 other studies available for moxonidine and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure.
Topics: Animals; Antihypertensive Agents; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Imidaz | 2013 |
Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cell Death; Cell Survival; Collagen; Cytokines; Ec | 2011 |
Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Blood Pressure; Capillaries; Captopril; | 2004 |
Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation.
Topics: Animals; Antihypertensive Agents; bcl-2-Associated X Protein; Blood Pressure; Caspase 3; Disease Mod | 2008 |
[Controlling blood pressure by centrally acting drugs--still a topic?].
Topics: Antihypertensive Agents; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Receptors, | 1994 |
Influence of different dietary salts on the cardiovascular and renal effects of moxonidine in spontaneously hypertensive rats.
Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Drinking; | 1997 |
[Efficacy of moxonidine, an imidazoline receptor agonist, in patients with essential hypertension].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Echocardiography; | 1998 |
[Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. Effects of moxonidine on coronary circulation].
Topics: Aged; Angina Pectoris; Antihypertensive Agents; Blood Flow Velocity; Coronary Circulation; Electroca | 2001 |